Mavacamten is used to treat a heart condition called hypertrophic cardiomyopathy, where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood effectively.[2] Camzyos is currently approved and in use across 3 indications[4].[1]
Camzyos is one of 97 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
687 competitors in Heart Failure
Camzyos
Bayer Aspirin
Amidate
Activase
Bystolic
Xifaxan
Zoloft
Xylocaine
Adriamycin
Neo-Synephrine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Apr 28, 2022
CAMZYOS
NDA NDA214998
Sources